Pharmaceutical giant Allergan announced that it would buy medicine unit LifeCell owned by Acelity for $2.9bn in cash.
Editor’s Remarks: Drugmaker Allergan agreed to another acquisition that sees its total M&A deals climbing to twelve this year alone. LifeCell is a regenerative unit that produces tissue products used in breast reconstruction and hernia surgeries. A spokesperson for the company announced that Allergan is hoping to increase its medical aesthetics portfolio, in an acquisition strategy that has been described as one of the ‘stepping stones’. A number of deals that Allergan has been involved in during the year have been dropped due to changes in the law, and Trump’s presidency in 2017 could see a change in competition laws that prevent this deal from passing.
What to watch: Allergan, LifeCell, Acelity, Trump, M&A